Market Overview

Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Share:
Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Many traders are stepping away from the market in the last week of the year to celebrate the holiday season with friends and family. However, biotech traders know the market never takes a vacation. In fact, there are a number of major biotech catalysts expected out in the near future.

Here’s a look at several biotech catalysts that could come in the closing days of 2016.

9 Catalysts Left For 2016

1. Cempra Inc (NASDAQ: CEMP)

The company’s Solithromycin therapy was granted qualified infectious diseases product (QIDP) designation back in August, and the drug has PDUFA dates of Tuesday and Wednesday.

2. Agios Pharmaceuticals Inc (NASDAQ: AGIO)

An NDA filing related to drug candidate AG-221 in treatment of advanced hematologic malignancies with an IDH2 mutation is due by the end of 2016.

3. Anthera Pharmaceuticals Inc (NASDAQ: ANTH)

By the end of Q4, the company is expected to report top-line Phase III data on Sollpura in treatment of cystic fibrosis patients who suffer from exocrine pancreatic insufficiency.

4. Aviragen Therapeutics Inc (NASDAQ: AVIR)

The company is expected to report top-line data on its Phase II study of BTA585 treatment of respiratory syncytial virus in the near future.

5. Coherus Biosciences Inc (NASDAQ: CHRS)

The company is expected to complete its Phase III confirmatory trial of CHS-1420 on treatment of psoriasis by the end of the year.

6. Nektar Therapeutics (NASDAQ: NKTR)

The company is expected to complete its Phase III trial of Cipro DPI in treatment of bronchiectasis by the end of Q4.

7. Opko Health Inc. (NASDAQ: OPK)

The company is expected to report Phase III data on HGH-CTP treatment of adults with growth hormone deficiency by the end fo Q4.

8. Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)

Phase II data on Fostamatinib in treatment of IgA nephropathy is expected by the end of the year.

9. TRACON Pharmaceuticals Inc (NASDAQ: TCON)

Phase II data on TRC105 I treatment of soft tissue sarcomas is expected out in the near future.

Posted-In: Biotech News Health Care Previews FDA Events Movers Trading Ideas Best of Benzinga

 

Related Articles (ANTH + AGIO)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

5 Takeaways From Wells Fargo's Vegas Room Rate Survey

What Prompted Fred's Pharmacy To Take The 'Poison Pill' And Adopt A Shareholder Rights Plan?